Skip to main content
Equibles
CPRX logo

CPRX · Catalyst Pharmaceuticals, Inc.

Track CPRX — free

Use CPRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CPRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
Market Cap
$3.85B
Shares
122.38M

Catalyst Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Catalyst Pharmaceuticals, Inc. (CPRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲42.7% $43.09M $13.24M '22 Q1 22-03-31 ▲46.1% $53.11M $21.62M '22 Q2 22-06-30 ▲59.2% $57.24M $22.75M '22 Q3 22-09-30 ▲58.6% $60.76M $25.47M '22 Q4 22-12-31 ▲98.1% $85.37M $29.57M '23 Q1 23-03-31 ▲87.5% $99.58M $37.76M '23 Q2 23-06-30 ▲79.4% $102.69M −$30.76M '23 Q3 23-09-30 ▲82% $110.57M $34.84M '23 Q4 23-12-31 ▲15.4% $98.51M $23.27M '24 Q1 24-03-31 ▲23.2% $122.71M $40.79M '24 Q2 24-06-30 ▲25.3% $128.69M $43.88M '24 Q3 24-09-30 ▲28.3% $141.82M $55.94M '24 Q4 24-12-31 ▲43.6% $141.42M $56.74M '25 Q1 25-03-31 ▲19.4% $146.56M $52.11M '25 Q2 25-06-30 ▲15.3% $148.39M $52.78M '25 Q3 25-09-30 LATEST ▲7.6% $152.61M $52.70M '25 Q4 26-02-26
Earnings call
FY25 · Q4
2026-02-26
Catalyst Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone FIRDAPSE commercial performance and LEMS growth AGAMREE launch and DMD growth Business development and pipeline expansion
Revenue
$152.61M*
▲ 7.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone FYCOMPA generic erosion AGAMREE growth FIRDAPSE performance
Revenue
$148.39M
▲ 15.3% YoY
Diluted EPS
$0.42
▲ 20% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone FIRDAPSE growth and LEMS franchise AGAMREE commercial momentum in Duchenne Clinical pipeline and lifecycle management
Revenue
$146.56M
▲ 19.4% YoY
Diluted EPS
$0.41
▲ 24.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone AGAMREE launch and uptake FIRDAPSE commercial performance FYCOMPA exclusivity transition
Revenue
$141.42M
▲ 43.6% YoY
Diluted EPS
$0.45
▲ 136.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Catalyst Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone FIRDAPSE Franchise AGAMREE Launch and Adoption FYCOMPA Lifecycle / Erosion
Revenue
$141.82M*
▲ 28.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone AGAMREE launch and growth FIRDAPSE commercial performance Full-year 2024 guidance raise
Revenue
$128.69M
▲ 25.3% YoY
Diluted EPS
$0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone FIRDAPSE organic growth and LEMS AGAMREE launch in Duchenne Muscular Dystrophy Full-year 2024 revenue guidance update
Revenue
$122.71M
▲ 23.2% YoY
Diluted EPS
$0.33
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone AGAMREE launch FIRDAPSE commercial performance Regulatory milestones
Revenue
$98.51M
▲ 15.4% YoY
Diluted EPS
$0.19
▼ 26.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Catalyst Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Revenue
$110.57M*
▲ 82% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$102.69M
▲ 79.4% YoY
Diluted EPS
$-0.29
▼ 245% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$99.58M
▲ 87.5% YoY
Diluted EPS
$0.33
▲ 65% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$85.37M
▲ 98.1% YoY
Diluted EPS
$0.26
▲ 116.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Catalyst Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$60.76M*
▲ 58.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$57.24M
▲ 59.2% YoY
Diluted EPS
$0.20
▲ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$53.11M
▲ 46.1% YoY
Diluted EPS
$0.20
▲ 81.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$43.09M
▲ 42.7% YoY
Diluted EPS
$0.12
▲ 71.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Catalyst Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$38.31M*
▲ 23.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$35.95M
▲ 22.6% YoY
Diluted EPS
$0.10
▼ 75.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$36.37M
▲ 22.8% YoY
Diluted EPS
$0.11
▲ 22.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$30.20M
▲ 3.7% YoY
Diluted EPS
$0.07
▼ 30% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Catalyst Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$31.01M*
▲ 3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Catalyst Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$29.32M
▼ 5.1% YoY
Diluted EPS
$0.41
▲ 215.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Catalyst Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$29.61M
▲ 2.7% YoY
Diluted EPS
$0.09
▼ 10% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Catalyst Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$29.14M
▲ 134.1% YoY
Diluted EPS
$0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1369568 CUSIP 14888U101 13F (30d) 350 filings 348 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)